# Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation

> **NCT02196857** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 16 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** Azacytidine
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT02196857
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-06
- **Primary completion:** 2018-11-27
- **Final completion:** 2018-11-27
- **Target enrollment:** 16 (ACTUAL)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02196857

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02196857, "Sorafenib Plus 5-Azacitidine Initial Therapy of Patients With Acute Myeloid Leukemia (AML) and High Risk Myelodysplastic Syndrome (MS) With FLT3-ITD Mutation". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02196857. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*